Approval · Notice of Compliance 37239 · 2026
MINT-CELECOXIB: Notice of Compliance 37239
Issued April 1, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37239
- Date
- April 1, 2026
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph
- Canadian reference product
- CELEBREX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-CELECOXIB | Not yet assigned | — |